Discovery of 7-oxopyrazolo[1,5-a]pyrimidine-6-carboxamides as potent and selective CB2 cannabinoid receptor inverse agonists

Journal of Medicinal Chemistry

Volumn 56, Issue 11, 2013, Pages 4482-4496

  Aghazadeh Tabrizi, Mojgan ^a   Baraldi, Pier Giovanni ^a   Saponaro, Giulia ^a   Moorman, Allan R ^b,e   Romagnoli, Romeo ^a   Preti, Delia ^a   Baraldi, Stefania ^a   Ruggiero, Emanuela ^a   Tintori, Cristina ^c   Tuccinardi, Tiziano ^d   Vincenzi, Fabrizio ^a   Borea, Pier Andrea ^a   Varani, Katia ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b King Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF SIENA   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e Alta Vetta Pharmaceutical Consulting LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; CANNABINOID 2 RECEPTOR AGONIST; ETHYL 2 (2 CHLOROPHENYL) 4,7 DIHYDRO 7 OXO 4 PENTYLPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 2 (2 CHLOROPHENYL) 4,7 DIHYDRO 7 OXOPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 2 (2,4 DICHLOROPHENYL) 4,7 DIHYDRO 7 OXO 4 PENTYLPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 2 (2,4 DICHLOROPHENYL) 4,7 DIHYDRO 7 OXOPYRAZOLO [1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 2 (2,6 DICHLOROPHENYL) 4,7 DIHYDRO 7 OXO 4 PENTYLPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 2 (2,6 DICHLOROPHENYL) 4,7 DIHYDRO 7 OXOPYRAZOLO [1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 2 (4 CHLOROPHENYL) 4,7 DIHYDRO 7 OXO 4 PENTYLPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 2 (4 CHLOROPHENYL) 4,7 DIHYDRO 7 OXOPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 2 ETHYL 4,7 DIHYDRO 7 OXO 4 PENTYLPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 2 TERT BUTYL 4,7 DIHYDRO 7 OXO 4 PENTYLPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 2 TERT BUTYL 4,7 DIHYDRO 7 OXOPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 3 BROMO 4,7 DIHYDRO 2 METHYL 7 OXOPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 4,7 DIHYDRO 2 (2 METHYLPHENYL ) 7 OXO 4 PENTYLPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 4,7 DIHYDRO 2 (2 METHYLPHENYL) 7 OXOPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 4,7 DIHYDRO 2 (4 METHYLPHENYL ) 7 OXO 4 PENTYLPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 4,7 DIHYDRO 2 (4 METHYLPHENYL) 7 OXOPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 4,7 DIHYDRO 2 (4 METHYLTHIOPHEN 2 YL ) 7 OXOPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 4,7 DIHYDRO 2 (5 METHYLTHIOPHEN 2 YL) 7 OXOPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 4,7 DIHYDRO 2 (FURAN 2 YL) 7 OXO 4 PENTYLPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 4,7 DIHYDRO 2 (FURAN 2 YL) 7 OXOPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 4,7 DIHYDRO 2 (FURAN 3 YL) 7 OXOPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 4,7 DIHYDRO 2 ETHYL 7 OXOPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 4,7 DIHYDRO 2 METHYL 7 OXO 4 PENTYLPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 4,7 DIHYDRO 2 METHYL 7 OXOPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 4,7 DIHYDRO 7 OXO 2 (THIOPHEN 2 YL)PYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 4,7 DIHYDRO 7 OXO 2 PHENYLPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; ETHYL 4,7 DIHYDRO 7 OXO 4 PENTYL 2 PHENYLPYRAZOLO[1,5 ALPHA]PYRIMIDINE 6 CARBOXYLATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; DRUG DESIGN; DRUG SYNTHESIS; ISOMER; MALE; MUTAGENESIS; NONHUMAN; PHARMACOPHORE; RAT;

AMIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; DRUG INVERSE AGONISM; HUMANS; MALE; MODELS, MOLECULAR; PYRAZOLES; PYRIMIDINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84879065619     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400182t     Document Type: Article

References (47)

1. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 1990, 346, 561-564
2. Gerard, C. M.; Mollereau, C.; Vassart, G.; Parmentier, M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis Biochem. J. 1991, 279, 129-134
3. Adams, I. B.; Martin, B. R. Cannabis: pharmacology and toxicology in animals and humans Addiction 1996, 91, 1585-1614 (Pubitemid 26393422)
4. 2 Pharmacol. Rev. 2010, 62, 588-631
5. Freund, T. F.; Katona, I.; Piomelli, D. Role of endogenous cannabinoids in synaptic signaling Physiol. Rev. 2003, 83, 1017-1066 (Pubitemid 36828930)
6. Patel, K. D.; Davison, J. S.; Pittman, Q. J.; Sharkey, K. A. Cannabinoid CB(2) receptors in health and disease Curr. Med. Chem. 2010, 17, 1393-1410
7. 2 receptors in human brain inflammation Br. J. Pharmacol. 2008, 153, 277-285
8. Howlett, A. C.; Barth, F. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors Pharmacol. Rev. 2002, 54, 161-202 (Pubitemid 34575709)
9. Rinaldi-Carmona, M.; Barth, F.; Millan, J.; Derocq, J. M.; Casellas, P.; Congy, C.; Oustric, D.; Sarran, M.; Bouaboula, M.; Calandra, B.; Portier, M.; Shire, D.; Breliere, J. C.; Le Fur, G. L. SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor J. Pharmacol. Exp. Ther. 1998, 284, 644-650 (Pubitemid 28086654)
10. 2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression Eur. J. Biochem. 1996, 237, 704-711
11. 2 receptors Mol. Pharmacol. 1995, 48, 443-450
12. 2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain Br. J. Pharmacol. 2008, 153, 319-334
13. Quartilho, A.; Mata, H. P.; Ibrahim, M. M.; Vanderah, T. W.; Porreca, F.; Makriyannis, A.; Malan, T. P. J. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors Anesthesiology 2003, 99, 955-960 (Pubitemid 37186088)
14. Ibrahim, M. M.; Deng, H.; Zvonok, A.; Cockayne, D. A.; Kwan, J.; Mata, H. P.; Vanderah, T. W.; Lai, J.; Porreca, F.; Makriyannis, A.; Malan, T. P., Jr. Activation of the CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 10529-10533 (Pubitemid 37071912)
15. Vincenzi, F.; Targa, M.; Corciulo, C.; Aghazadeh Tabriz, M.; Merighi, S.; Gessi, S.; Saponaro, G.; Baraldi, P. G.; Borea, P. A.; Varani, K. Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models Pain 2013, 154, 864-873
16. Ashton, J. C.; Glass, M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration Curr. Neuropharmacol. 2007, 5, 73-80 (Pubitemid 47019422)
17. Lunn, C. A.; Reich, E. P.; Fine, J. S.; Lavey, B.; Kozlowski, J. A.; Hipkin, R. W.; Lundell, D. J.; Bober, L. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists Br. J. Pharmacol. 2008, 153, 226-239
18. Yang, P.; Wang, L.; Feng, R.; Almehizia, A. A.; Tong, Q.; Myint, K.-Z.; Ouyang, Q.; Alqarni, M. A.; Wang, L.; Xie, X.-Q. Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation J. Med. Chem. 2013, 56, 2045-2058
19. Huffman, J. W.; Zengin, G.; Wu, M. J.; Lu, J.; Hynd, G.; Bushell, K.; Thompson, A. L.; Bushell, S.; Tartal, C.; Hurst, D. P.; Reggio, P. H.; Selley, D. E.; Cassidy, M. P.; Wiley, J. L.; Martin, B. R. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists Bioorg. Med. Chem. 2005, 13, 89-112 (Pubitemid 39575695)
20. Muccioli, G. G.; Lambert, D. M. Current knowledge on the antagonists and inverse agonists of cannabinoid receptors Curr. Med. Chem. 2005, 12, 1361-1394 (Pubitemid 40872582)
21. 2 cannabinoid receptors of L759633, L759656 and AM630 Br. J. Pharmacol. 1999, 126, 665-672 (Pubitemid 29087845)
22. 2 receptor J. Pharmacol. Exp. Ther. 2001, 296, 420-425 (Pubitemid 32112468)
23. 2 receptor inverse agonist JTE-907 suppresses spontaneous itchassociated responses of NC mice, a model of atopic dermatitis Eur. J. Pharmacol. 2006, 542, 179-183 (Pubitemid 44066370)
24. 2 receptor inhibitors: identification of a lead and initial SAR studies Bioorg. Med. Chem. Lett. 2005, 15, 783-786 (Pubitemid 40143165)
25. 2 receptor inverse agonists Br. J. Pharmacol. 2008, 153, 226-239
26. Baraldi, P. G.; Saponaro, G.; Moorman, A. R.; Romagnoli, R.; Preti, D.; Baraldi, S.; Ruggiero, E.; Varani, K.; Targa, M.; Vincenzi, F.; Borea, P. A.; Aghazadeh Tabrizi, M. 7-Oxo-[1,4]oxazino[2,3,4- ij ]quinoline-6-carboxamides as selective CB(2) cannabinoid receptor ligands: structural investigations around a novel class of full agonists J. Med. Chem. 2012, 55, 6608-6623
27. Aghazadeh Tabrizi, M.; Baraldi, P. G.; Saponaro, G.; Moorman, A.; Romagnoli, R.; Preti, D.; Baraldi, S.; Corciulo, C.; Vincenzic, F.; Borea, P. A.; Varani, K. Design, synthesis, and pharmacological properties of new heteroarylpyridine/ heteroarylpyrimidine derivatives as CB2 cannabinoid receptor partial agonists J. Med. Chem. 2013, 56, 1098-1112
28. Ji, Y.; Trenkle, W. C.; Vowles, J. V. A high-yielding preparation of β-ketonitriles Org. Lett. 2006, 8, 1161-1163
29. Ochiai, H.; Ishida, A.; Ohtani, T.; Kusumi, K.; Kishikawa, K.; Yamamoto, S.; Takeda, H.; Obata, T.; Nakai, H.; Toda, M. Discovery of new orally active phosphodiesterase (PDE4) inhibitors Chem. Pharm. Bull. 2004, 52, 1098-1104 (Pubitemid 41679550)
30. Chu, I.; Lynch, B. M. Synthesis and biological evaluation of xanthine oxidase inhibitors. Pyrazolo[3,4- d ]pyrimidines and pyrazolo[3,4- b ]pyridines J. Med. Chem. 1975, 18, 161-165
31. Griffin, G.; Tao, Q.; Abood, M. E. Cloning and pharmacological characterization of the rat CB2 cannabinoid receptor J. Pharmacol. Exp. Ther. 2000, 292, 886-894 (Pubitemid 30136579)
32. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function J. Comput. Chem. 1998, 19, 1639-1662 (Pubitemid 128590223)
33. Song, Z. H.; Slowey, C. A.; Hurst, D. P.; Reggio, P. H. The difference between the CB(1) and CB(2) cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB(2) Mol. Pharmacol. 1999, 56, 834-840 (Pubitemid 29491187)
34. Manera, C.; Tuccinardi, T.; Martinelli, A. Indoles and related compounds as cannabinoid ligands Mini-Rev. Med. Chem. 2008, 8, 370-387 (Pubitemid 351606778)
35. McAllister, S. D.; Rizvi, G.; Anavi-Goffer, S.; Hurst, D. P.; Barnett-Norris, J.; Lynch, D. L.; Reggio, P. H.; Abood, M. E. An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region J. Med. Chem. 2003, 46, 5139-5152 (Pubitemid 37414184)
36. 1 cannabinoid receptor: biochemical and pharmacological characterization J. Pharmacol. Exp. Ther. 2004, 310, 905-914 (Pubitemid 39108910)
37. 2 receptors Br. J. Pharmacol. 1998, 124, 619-622 (Pubitemid 28276796)
38. 2 receptors Biochem. Pharmacol. 2010, 79, 471-477
39. 3 adenosine receptors Mol. Pharmacol. 2000, 57, 968-975 (Pubitemid 30253381)
40. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-108
41. Munson, P. J.; Rodbard, D. Ligand: a versatile computerized approach for characterization of ligand-binding systems Anal. Biochem. 1980, 107, 220-239
42. Maestro, version 9.0; Schrödinger Inc: Portland, OR, 2009.
43. Macromodel, version 9.7; Schrödinger Inc: Portland, OR, 2009.
44. 1 selectivity. Receptor modeling and automated docking analysis J. Med. Chem. 2006, 49, 984-994 (Pubitemid 43221646)
45. 2A receptor structures reveal common features of GPCR activation Nature 2011, 474, 521-525
46. Choe, H. W.; Kim, Y. J.; Park, J. H.; Morizumi, T.; Pai, E. F.; Krauss, N.; Hofmann, K. P.; Scheerer, P.; Ernst, O. P. Crystal structure of metarhodopsin II Nature 2011, 471, 651-655
47. Sanner, M. F. Python: a programming language for software integration and development J. Mol. Graphics Modell. 1999, 17, 57-61